Published in Cancer Weekly, January 17th, 2006
The company has added a $50 million accordion feature to the facility, which allows it to increase the aggregate principal amount of the term B financing to $150 million, at the company's option.
The $100 million term B loan has an initial interest rate spread of 200 basis points, with the opportunity to permanently reduce the spread to 175 basis points after 6 months, provided the company's leverage ratio is below 2:1.
The company used the proceeds of the term B loan to pay off its pre-existing term A loan as well as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.